PerkinElmer Announces Financial Results for the Third Quarter of 2021

  • Revenue of $1.17 billion; 21% reported growth; 12% organic growth
  • GAAP EPS from continuing operations of $1.11; Adjusted EPS of $2.31
  • Initiates Fourth Quarter Guidance and Raises Full Year Revenue and Earnings Guidance

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 3, 2021.

The Company reported GAAP earnings per share from continuing operations of $1.11, as compared to GAAP earnings per share from continuing operations of $1.57 in the third quarter of 2020. GAAP revenue for the quarter was $1.17 billion, as compared to $964 million in the third quarter of 2020. GAAP operating income from continuing operations for the quarter was $222 million, as compared to $248 million for the same period a year ago. GAAP operating profit margin was 19.0% as a percentage of revenue, as compared to 25.7% in the third quarter of 2020.

Adjusted earnings per share from continuing operations for the quarter was $2.31, as compared to $2.09 in the third quarter of 2020. Adjusted revenue for the quarter was $1.17 billion, as compared to $964 million in the third quarter of 2020. Adjusted operating income from continuing operations for the quarter was $359 million, as compared to $304 million for the same period a year ago. Adjusted operating profit margin was 30.8% as a percentage of adjusted revenue, as compared to 31.6% in the third quarter of 2020.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“I am proud of the team’s tireless efforts to proactively respond to and execute for our customers around the world, driving double digit core growth in all major regions during the third quarter,” said Prahlad Singh, president and chief executive officer of PerkinElmer. “Just as importantly, we are embracing new opportunities as we welcome the latest additions to the PerkinElmer family and develop innovative solutions to push the boundaries of what’s possible.”

Financial Overview by Reporting Segment for the Third Quarter

Discovery & Analytical Solutions

  • Third quarter 2021 revenue was $513 million, as compared to $424 million for the third quarter of 2020. Reported revenue increased 21% and organic revenue increased 10% as compared to the third quarter of 2020.
  • Third quarter 2021 operating income from continuing operations was $7 million, as compared to $43 million for the third quarter of 2020.
  • Third quarter 2021 adjusted operating income was $95 million, as compared to $62 million for the third quarter of 2020.

Diagnostics

  • Third quarter 2021 revenue was $654 million, as compared to $540 million for the third quarter of 2020. Reported revenue increased 21% and organic revenue increased 13% as compared to the third quarter of 2020.
  • Third quarter 2021 operating income from continuing operations was $238 million, as compared to $224 million for the third quarter of 2020.
  • Third quarter 2021 adjusted operating income was $287 million, as compared to $260 million for the third quarter of 2020.

Initiates Fourth Quarter Guidance and Raises Full Year 2021 Guidance

For the fourth quarter of 2021, the Company forecasts adjusted revenue of approximately $1.2 billion and adjusted earnings per share of $2.05.

For the full year 2021, the Company now forecasts adjusted revenue of $4.9 billion and adjusted earnings per share of $10.81.

Guidance for the fourth quarter and full year is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Conference Call and Webcast Information

The Company will discuss its third quarter 2021 results and its outlook for business trends during a conference call on November 2, 2021 at 5:00 p.m. Eastern Time. A live audio webcast of the call will be available on the Investors section of the Company’s website, www.perkinelmer.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “estimates”, “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions, such as BioLegend, and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom’s withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 15,000 employees serving customers in more than 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com.

PerkinElmer, Inc. and Subsidiaries

CONDENSED CONSOLIDATED INCOME STATEMENTS

 
 

Three Months Ended

 

Nine Months Ended

(In thousands, except per share data)

October 3, 2021

 

October 4, 2020

 

October 3, 2021

 

October 4, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

$

1,166,684

 

 

$

964,025

 

 

$

3,702,844

 

 

$

2,428,139

 

 

 

 

 

 

 

 

Cost of revenue

 

534,848

 

 

 

436,580

 

 

 

1,600,668

 

 

 

1,145,327

 

Selling, general and administrative expenses

 

339,047

 

 

 

225,249

 

 

 

872,276

 

 

 

654,844

 

Research and development expenses

 

68,608

 

 

 

50,131

 

 

 

194,648

 

 

 

148,566

 

Restructuring and other costs, net

 

2,211

 

 

 

4,059

 

 

 

13,018

 

 

 

11,075

 

 

 

 

 

 

 

 

Operating income from continuing operations

 

221,970

 

 

 

248,006

 

 

 

1,022,234

 

 

 

468,327

 

 

 

 

 

 

 

 

Interest income

 

(544

)

 

 

(205

)

 

 

(1,322

)

 

 

(662

)

Interest expense

 

43,531

 

 

 

12,057

 

 

 

74,407

 

 

 

37,308

 

Change in fair value of financial securities

 

19,365

 

 

 

(35

)

 

 

(8,566

)

 

 

(35

)

Other (income) expense, net

 

(2,050

)

 

 

2,432

 

 

 

(10,492

)

 

 

(1,557

)

 

 

 

 

 

 

 

Income from continuing operations, before income taxes

 

161,668

 

 

 

233,757

 

 

 

968,207

 

 

 

433,273

 

 

 

 

 

 

 

 

Provision for income taxes

 

33,883

 

 

 

57,021

 

 

 

215,111

 

 

 

85,609

 

 

 

 

 

 

 

 

Income from continuing operations

 

127,785

 

 

 

176,736

 

 

 

753,096

 

 

 

347,664

 

 

 

 

 

 

 

 

Loss on disposition of discontinued operations, before income taxes

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes on discontinued operations and dispositions

 

47

 

 

 

37

 

 

 

123

 

 

 

138

 

 

 

 

 

 

 

 

Loss from discontinued operations and dispositions

 

(47

)

 

 

(37

)

 

 

(123

)

 

 

(138

)

 

 

 

 

 

 

 

Net income

$

127,738

 

 

$

176,699

 

 

$

752,973

 

 

$

347,526

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share:

 

 

 

 

 

 

 

Income from continuing operations

$

1.11

 

 

$

1.57

 

 

$

6.65

 

 

$

3.11

 

 

 

 

 

 

 

 

Loss from discontinued operations and dispositions

 

(0.00

)

 

 

(0.00

)

 

 

(0.00

)

 

 

(0.00

)

 

 

 

 

 

 

 

Net income

$

1.11

 

 

$

1.57

 

 

$

6.65

 

 

$

3.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average diluted shares of common stock outstanding

 

115,022

 

 

 

112,292

 

 

 

113,307

 

 

 

111,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ABOVE PREPARED IN ACCORDANCE WITH GAAP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional Supplemental Information (1):

 

 

 

 

 

 

 

(per share, continuing operations)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP EPS from continuing operations

$

1.11

 

 

$

1.57

 

 

$

6.65

 

 

$

3.11

 

Amortization of intangible assets

 

0.62

 

 

 

0.44

 

 

 

1.63

 

 

 

1.28

 

Purchase accounting adjustments

 

0.09

 

 

 

0.03

 

 

 

0.17

 

 

 

(0.06

)

Acquisition and divestiture-related costs

 

0.63

 

 

 

0.00

 

 

 

0.77

 

 

 

0.07

 

Change in fair value of financial securities

 

0.17

 

 

 

(0.00

)

 

 

(0.08

)

 

 

(0.00

)

Asset impairment

 

0.03

 

 

 

 

 

 

0.03

 

 

 

 

Significant litigation matters and settlements

 

 

 

 

 

 

 

 

 

 

0.03

 

Significant environmental matters

 

 

 

 

 

 

 

 

 

 

0.05

 

Disposition of businesses and assets, net

 

(0.02

)

 

 

 

 

 

(0.02

)

 

 

 

Restructuring and other, net

 

0.02

 

 

 

0.04

 

 

 

0.11

 

 

 

0.10

 

Tax on above items

 

(0.34

)

 

 

(0.12

)

 

 

(0.55

)

 

 

(0.37

)

Significant tax items

 

(0.01

)

 

 

0.14

 

 

 

0.12

 

 

 

0.14

 

Adjusted EPS

$

2.31

 

 

$

2.09

 

 

$

8.84

 

 

$

4.33

 

 
(1) amounts may not sum due to rounding
 
 
PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
 
 
 
Three Months Ended Nine Months Ended
(In thousands, except percentages) October 3, 2021 October 4, 2020 October 3, 2021 October 4, 2020
 
 
DAS Reported revenue

$

512,879

 

$

423,623

 

$

1,480,317

 

$

1,213,020

 

Purchase accounting adjustments

 

 

1,849

 

 

Adjusted revenue

512,879

 

423,623

 

1,482,166

 

1,213,020

 

 
Reported operating income from continued operations

7,146

 

42,689

 

114,248

 

110,632

 

OP%

1.4

%

10.1

%

7.7

%

9.1

%

Amortization of intangible assets

33,437

 

17,607

 

76,929

 

58,823

 

Purchase accounting adjustments

5,673

 

 

9,322

 

(11,334

)

Acquisition and divestiture-related costs

47,059

 

212

 

61,564

 

7,045

 

Significant litigation matters and settlements

 

 

 

2,399

 

Restructuring and other, net

1,624

 

1,979

 

9,368

 

6,733

 

Adjusted operating income

94,939

 

62,487

 

271,431

 

174,298

 

Adjusted OP%

18.5

%

14.8

%

18.3

%

14.4

%

 
Diagnostics Reported revenue

653,805

 

540,402

 

2,222,527

 

1,215,119

 

Purchase accounting adjustments

199

 

196

 

597

 

588

 

Adjusted revenue

654,004

 

540,598

 

2,223,124

 

1,215,707

 

 
Reported operating income from continued operations

237,903

 

223,819

 

965,650

 

413,710

 

OP%

36.4

%

41.4

%

43.4

%

34.0

%

Amortization of intangible assets

37,517

 

31,292

 

107,743

 

84,043

 

Purchase accounting adjustments

5,107

 

3,107

 

9,485

 

4,872

 

Asset impairment

3,868

 

 

3,868

 

 

Acquisition and divestiture-related costs

2,023

 

18

 

7,833

 

323

 

Significant litigation matters and settlements

 

 

 

1,245

 

Restructuring and other, net

587

 

2,080

 

3,650

 

4,342

 

Adjusted operating income

287,005

 

260,316

 

1,098,229

 

508,535

 

Adjusted OP%

43.9

%

48.2

%

49.4

%

41.8

%

 
Corporate Reported operating loss

(23,079

)

(18,502

)

(57,664

)

(56,015

)

Significant environmental matters

 

 

 

5,242

 

Adjusted operating loss

(23,079

)

(18,502

)

(57,664

)

(50,773

)

 
Continuing Operations Reported revenue

$

1,166,684

 

$

964,025

 

$

3,702,844

 

$

2,428,139

 

Purchase accounting adjustments

199

 

196

 

2,446

 

588

 

Adjusted revenue

1,166,883

 

964,221

 

3,705,290

 

2,428,727

 

 
Reported operating income from continued operations

221,970

 

248,006

 

1,022,234

 

468,327

 

OP%

19.0

%

25.7

%

27.6

%

19.3

%

Amortization of intangible assets

70,954

 

48,899

 

184,672

 

142,866

 

Purchase accounting adjustments

10,780

 

3,107

 

18,807

 

(6,462

)

Acquisition and divestiture-related costs

49,082

 

230

 

69,397

 

7,368

 

Asset impairment

3,868

 

 

3,868

 

 

Significant litigation matters and settlements

 

 

 

3,644

 

Significant environmental matters

 

 

 

5,242

 

Restructuring and other, net

2,211

 

4,059

 

13,018

 

11,075

 

Adjusted operating income

$

358,865

 

$

304,301

 

$

1,311,996

 

$

632,060

 

Adjusted OP%

30.8

%

31.6

%

35.4

%

26.0

%

 
 
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
 

(In thousands)

October 3, 2021 January 3, 2021

 

Current assets:

Cash and cash equivalents

$

487,373

$

402,036

Accounts receivable, net

 

947,805

 

1,155,109

Inventories

 

645,419

 

514,567

Other current assets

 

170,207

 

167,208

Total current assets

 

2,250,804

 

2,238,920

 

Property, plant and equipment, net

 

537,710

 

368,304

Operating lease right-of-use assets

 

208,661

 

207,236

Intangible assets, net

 

4,160,736

 

1,365,693

Goodwill

 

7,420,271

 

3,447,114

Other assets, net

 

321,667

 

333,048

Total assets

$

14,899,849

$

7,960,315

 

Current liabilities:

Current portion of long-term debt

$

4,485

$

380,948

Accounts payable

 

320,435

 

327,325

Accrued expenses and other current liabilities

 

820,109

 

943,916

Total current liabilities

 

1,145,029

 

1,652,189

 

Long-term debt

 

5,099,077

 

1,609,701

Long-term liabilities

 

1,512,153

 

774,531

Operating lease liabilities

 

185,005

 

188,402

Total liabilities

 

7,941,264

 

4,224,823

 

Total stockholders’ equity

 

6,958,585

 

3,735,492

Total liabilities and stockholders’ equity

$

14,899,849

$

7,960,315

 
 
PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 

Three Months Ended

 

Nine Months Ended

October 3, 2021

October 4, 2020

 

October 3, 2021

October 4, 2020

(In thousands)

 

(In thousands)

 

 

 

 

 

 

 

Operating activities:

 

 

 

 

 

 

 

Net income

$

127,738

 

 

$

176,699

 

 

$

752,973

 

 

$

347,526

 

Loss from discontinued operations and dispositions, net of income taxes

 

47

 

 

 

37

 

 

 

123

 

 

 

138

 

Income from continuing operations

 

127,785

 

 

 

176,736

 

 

 

753,096

 

 

 

347,664

 

Adjustments to reconcile income from continuing operations

 

 

 

 

 

 

 

to net cash provided by continuing operations:

 

 

 

 

 

 

 

Stock-based compensation

 

6,597

 

 

 

7,117

 

 

 

18,957

 

 

 

19,770

 

Restructuring and other, net

 

2,211

 

 

 

4,059

 

 

 

13,018

 

 

 

11,075

 

Depreciation and amortization

 

87,113

 

 

 

62,474

 

 

 

232,935

 

 

 

182,521

 

Change in fair value of contingent consideration

 

1,076

 

 

 

2,639

 

 

 

1,553

 

 

 

(8,807

)

Amortization of deferred debt financing costs and accretion of discounts

 

1,500

 

 

 

917

 

 

 

3,224

 

 

 

2,559

 

Change in fair value of financial securities

 

19,365

 

 

 

 

 

 

(8,566

)

 

 

 

Amortization of acquired inventory revaluation

 

9,425

 

 

 

272

 

 

 

14,728

 

 

 

1,757

 

Loss on disposition of businesses and assets, net

 

(1,970

)

 

 

401

 

 

 

(1,970

)

 

 

886

 

Asset impairment

 

3,868

 

 

 

 

 

 

3,868

 

 

 

 

Changes in assets and liabilities which provided (used) cash, excluding

 

 

 

 

 

 

 

 

 

effects from companies acquired:

 

 

 

 

 

 

 

 

Accounts receivable, net

 

87,115

 

 

 

(72,007

)

 

 

242,386

 

 

 

(67,695

)

Inventories

 

(923

)

 

 

5,773

 

 

 

6,316

 

 

 

(120,934

)

Accounts payable

 

(10,206

)

 

 

(4,517

)

 

 

(37,002

)

 

 

16,391

 

Accrued expenses and other

 

(19,161

)

 

 

27,569

 

 

 

(167,385

)

 

 

24,893

 

Net cash provided by operating activities of continuing operations

 

313,795

 

 

 

211,433

 

 

 

1,075,158

 

 

 

410,080

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

Capital expenditures

 

(32,784

)

 

 

(20,253

)

 

 

(67,459

)

 

 

(57,391

)

Purchases of investments

 

(4,623

)

 

 

(2,166

)

 

 

(19,130

)

 

 

(9,559

)

Proceeds from surrender of life insurance policies

 

 

 

 

 

 

 

 

 

 

131

 

Proceeds from disposition of businesses and assets

 

1,460

 

 

 

608

 

 

 

1,460

 

 

 

2,423

 

Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired

 

(3,264,981

)

 

 

(712

)

 

 

(3,967,678

)

 

 

(3,702

)

Net cash used in investing activities of continuing operations

 

(3,300,928

)

 

 

(22,523

)

 

 

(4,052,807

)

 

 

(68,098

)

 

 

 

 

 

 

 

Financing Activities:

 

 

 

 

 

 

 

Payments on borrowings

 

(427,580

)

 

 

(225,210

)

 

 

(1,191,125

)

 

 

(515,210

)

Proceeds from borrowings

 

415,282

 

 

 

69,000

 

 

 

1,144,282

 

 

 

257,000

 

Proceeds from term loan

 

500,000

 

 

 

 

 

 

500,000

 

 

 

 

Payments of senior debt

 

 

 

 

 

 

 

(339,605

)

 

 

 

Proceeds from sale of senior debt

 

2,286,239

 

 

 

 

 

 

3,086,095

 

 

 

 

Payments of debt financing costs

 

(22,741

)

 

 

 

 

 

(30,983

)

 

 

 

Settlement of cash flow hedges

 

4,477

 

 

 

(7,126

)

 

 

(1,459

)

 

 

(2,089

)

Net payments on other credit facilities

 

(905

)

 

 

(2,088

)

 

 

(12,731

)

 

 

(8,124

)

Payments for acquisition-related contingent consideration

 

 

 

 

 

 

 

 

 

 

(5,200

)

Proceeds from issuance of common stock under stock plans

 

8,575

 

 

 

17,454

 

 

 

22,760

 

 

 

27,528

 

Purchases of common stock

 

(89

)

 

 

(159

)

 

 

(73,013

)

 

 

(6,829

)

Dividends paid

 

(7,842

)

 

 

(7,809

)

 

 

(23,539

)

 

 

(23,381

)

Net cash provided by (used in) financing activities of continuing operations

 

2,755,416

 

 

 

(155,938

)

 

 

3,080,682

 

 

 

(276,305

)

 

 

 

 

 

 

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(5,925

)

 

 

5,490

 

 

 

(16,584

)

 

 

832

 

 

 

 

 

 

 

 

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

(237,642

)

 

 

38,462

 

 

 

86,449

 

 

 

66,509

 

Cash, cash equivalents, and restricted cash at beginning of period

 

726,704

 

 

 

219,941

 

 

 

402,613

 

 

 

191,894

 

Cash, cash equivalents, and restricted cash at end of period

$

489,062

 

 

$

258,403

 

 

$

489,062

 

 

$

258,403

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:

 

 

 

 

 

 

 

Cash and cash equivalents

$

487,373

 

 

$

258,293

 

 

$

487,373

 

 

$

258,293

 

Restricted cash included in other current assets

 

1,689

 

 

 

110

 

 

 

1,689

 

 

 

110

 

Total cash, cash equivalents and restricted cash

$

489,062

 

 

$

258,403

 

 

$

489,062

 

 

$

258,403

 

 
PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

 

(In millions, except per share data and percentages)

 

PKI

 

Three Months Ended

 

October 3, 2021

October 4, 2020

 

Adjusted revenue:

 

Revenue

 

$

1,166.7

 

$

964.0

 

Purchase accounting adjustments

 

 

0.2

 

 

0.2

 

Adjusted revenue

 

$

1,166.9

 

$

964.2

 

 

Adjusted gross margin:

 

Gross margin

 

$

631.8

 

54.2

%

$

527.4

 

54.7

%

Amortization of intangible assets

 

 

32.1

 

2.8

%

 

16.7

 

1.7

%

Purchase accounting adjustments

 

 

9.6

 

0.8

%

 

0.5

 

0.0

%

Adjusted gross margin

 

$

673.5

 

57.7

%

$

544.6

 

56.5

%

 

Adjusted SG&A:

 

SG&A

 

$

339.0

 

29.1

%

$

225.2

 

23.4

%

Amortization of intangible assets

 

 

(38.9

)

-3.3

%

 

(32.2

)

-3.3

%

Purchase accounting adjustments

 

 

(1.2

)

-0.1

%

 

(2.6

)

-0.3

%

Acquisition and divestiture-related costs

 

 

(49.1

)

-4.2

%

 

(0.2

)

0.0

%

Asset impairment

 

 

(3.9

)

-0.3

%

 

 

0.0

%

Adjusted SG&A

 

$

246.1

 

21.1

%

$

190.2

 

19.7

%

 

R&D

 

$

68.6

 

5.9

%

$

50.1

 

5.2

%

 

Adjusted operating income:

 

Operating income

 

$

222.0

 

19.0

%

$

248.0

 

25.7

%

Amortization of intangible assets

 

 

71.0

 

6.1

%

 

48.9

 

5.1

%

Purchase accounting adjustments

 

 

10.8

 

0.9

%

 

3.1

 

0.3

%

Acquisition and divestiture-related costs

 

 

49.1

 

4.2

%

 

0.2

 

0.0

%

Asset impairment

 

 

3.9

 

0.3

%

 

 

0.0

%

Restructuring and other, net

 

 

2.2

 

0.2

%

 

4.1

 

0.4

%

Adjusted operating income

 

$

358.9

 

30.8

%

$

304.3

 

31.6

%

 

 

PKI

 

Three Months Ended

 

October 3, 2021

October 4, 2020

 

Adjusted EPS:

 

GAAP EPS

 

$

1.11

 

$

1.57

 

Discontinued operations, net of income taxes

 

 

(0.00

)

 

(0.00

)

GAAP EPS from continuing operations

 

 

1.11

 

 

1.57

 

Amortization of intangible assets

 

 

0.62

 

 

0.44

 

Purchase accounting adjustments

 

 

0.09

 

 

0.03

 

Acquisition and divestiture-related costs

 

 

0.63

 

 

0.00

 

Change in fair value of financial securities

 

 

0.17

 

 

(0.00

)

Asset impairment

 

 

0.03

 

 

 

Disposition of businesses and assets, net

 

 

(0.02

)

 

 

Restructuring and other, net

 

 

0.02

 

 

0.04

 

Tax on above items

 

 

(0.34

)

 

(0.12

)

Significant tax items

 

 

(0.01

)

 

0.14

 

Adjusted EPS

 

$

2.31

 

$

2.09

 

 

 

DAS

 

Three Months Ended

 

October 3, 2021

October 4, 2020

 

Adjusted revenue:

 

Revenue

 

$

512.9

 

$

423.6

 

Purchase accounting adjustments

 

 

 

 

 

Adjusted revenue

 

$

512.9

 

$

423.6

 

 

Adjusted operating income:

 

Operating income

 

$

7.1

 

1.4

%

$

42.7

 

10.1

%

Amortization of intangible assets

 

 

33.4

 

6.5

%

 

17.6

 

4.2

%

Purchase accounting adjustments

 

 

5.7

 

1.1

%

 

 

0.0

%

Acquisition and divestiture-related costs

 

 

47.1

 

9.2

%

 

0.2

 

0.1

%

Restructuring and other, net

 

 

1.6

 

0.3

%

 

2.0

 

0.5

%

Adjusted operating income

 

$

94.9

 

18.5

%

$

62.5

 

14.8

%

 

 

Diagnostics

 

Three Months Ended

 

October 3, 2021

October 4, 2020

 

Adjusted revenue:

 

Revenue

 

$

653.8

 

$

540.4

 

Purchase accounting adjustments

 

 

0.2

 

 

0.2

 

Adjusted revenue

 

$

654.0

 

$

540.6

 

 

Adjusted operating income:

 

Operating income

 

$

237.9

 

36.4

%

$

223.8

 

41.4

%

Amortization of intangible assets

 

 

37.5

 

5.7

%

 

31.3

 

5.8

%

Purchase accounting adjustments

 

 

5.1

 

0.8

%

 

3.1

 

0.6

%

Asset impairment

 

 

3.9

 

0.6

%

 

 

0.0

%

Acquisition and divestiture-related costs

 

 

2.0

 

0.3

%

 

0.0

 

0.0

%

Restructuring and other, net

 

 

0.6

 

0.1

%

 

2.1

 

0.4

%

Adjusted operating income

 

$

287.0

 

43.9

%

$

260.3

 

48.2

%

 

(1) amounts may not sum due to rounding

 

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
 
(In millions, except per share data and percentages) PKI

Nine Months Ended

October 3, 2021

October 4, 2020

 
Adjusted revenue:
Revenue

$

3,702.8

 

$

2,428.1

 

Purchase accounting adjustments

 

2.4

 

 

0.6

 

Adjusted revenue

$

3,705.3

 

$

2,428.7

 

 
Adjusted gross margin:
Gross margin

$

2,102.2

 

56.8

%

$

1,282.8

 

52.8

%

Amortization of intangible assets

 

75.1

 

2.0

%

 

48.8

 

2.0

%

Purchase accounting adjustments

 

17.2

 

0.5

%

 

2.3

 

0.1

%

Adjusted gross margin

$

2,194.4

 

59.2

%

$

1,333.9

 

54.9

%

 
Adjusted SG&A:
SG&A

$

872.3

 

23.6

%

$

654.8

 

27.0

%

Amortization of intangible assets

 

(109.6

)

-3.0

%

 

(94.1

)

-3.9

%

Purchase accounting adjustments

 

(1.6

)

0.0

%

 

8.8

 

0.4

%

Acquisition and divestiture-related costs

 

(69.4

)

-1.9

%

 

(7.4

)

-0.3

%

Asset impairment

 

(3.9

)

-0.1

%

 

 

0.0

%

Significant litigation matters and settlements

 

 

0.0

%

 

(3.6

)

-0.2

%

Significant environmental matters

 

 

0.0

%

 

(5.2

)

-0.2

%

Adjusted SG&A

$

687.8

 

18.6

%

$

553.3

 

22.8

%

 
R&D

$

194.6

 

5.3

%

$

148.6

 

6.1

%

 
Adjusted operating income:
Operating income

$

1,022.2

 

27.6

%

$

468.3

 

19.3

%

Amortization of intangible assets

 

184.7

 

5.0

%

 

142.9

 

5.9

%

Purchase accounting adjustments

 

18.8

 

0.5

%

 

(6.5

)

-0.3

%

Acquisition and divestiture-related costs

 

69.4

 

1.9

%

 

7.4

 

0.3

%

Asset impairment

 

3.9

 

0.1

%

 

 

0.0

%

Significant litigation matters and settlements

 

 

0.0

%

 

3.6

 

0.2

%

Significant environmental matters

 

 

0.0

%

 

5.2

 

0.2

%

Restructuring and other, net

 

13.0

 

0.4

%

 

11.1

 

0.5

%

Adjusted operating income

$

1,312.0

 

35.4

%

$

632.1

 

26.0

%

 
PKI

Nine Months Ended

October 3, 2021

October 4, 2020

 
Adjusted EPS:
GAAP EPS

$

6.65

 

$

3.10

 

Discontinued operations

 

(0.00

)

 

(0.00

)

GAAP EPS from continuing operations

 

6.65

 

 

3.11

 

Amortization of intangible assets

 

1.63

 

 

1.28

 

Purchase accounting adjustments

 

0.17

 

 

(0.06

)

Significant litigation matters and settlements

 

 

 

0.03

 

Significant environmental matters

 

 

 

0.05

 

Acquisition and divestiture-related costs

 

0.77

 

 

0.07

 

Change in fair value of financial securities

 

(0.08

)

 

(0.00

)

Asset impairment

 

0.03

 

 

 

Disposition of businesses and assets, net

 

(0.02

)

 

 

Restructuring and other, net

 

0.11

 

 

0.10

 

Tax on above items

 

(0.55

)

 

(0.37

)

Significant tax items

 

0.12

 

 

0.14

 

Adjusted EPS

$

8.84

 

$

4.33

 

 
DAS

Nine Months Ended

October 3, 2021

October 4, 2020

 
Adjusted revenue:
Revenue

$

1,480.3

 

$

1,213.0

 

Purchase accounting adjustments

 

1.8

 

 

 

Adjusted revenue

$

1,482.2

 

$

1,213.0

 

 
Adjusted operating income:
Operating income

$

114.2

 

7.7

%

$

110.6

 

9.1

%

Amortization of intangible assets

 

76.9

 

5.2

%

 

58.8

 

4.8

%

Purchase accounting adjustments

 

9.3

 

0.6

%

 

(11.3

)

-0.9

%

Acquisition and divestiture-related costs

 

61.6

 

4.2

%

 

7.0

 

0.6

%

Significant litigation matters and settlements

 

 

0.0

%

 

2.4

 

0.2

%

Restructuring and other, net

 

9.4

 

0.6

%

 

6.7

 

0.6

%

Adjusted operating income

$

271.4

 

18.3

%

$

174.3

 

14.4

%

 
Diagnostics

Nine Months Ended

October 3, 2021

October 4, 2020

 
Adjusted revenue:
Revenue

$

2,222.5

 

$

1,215.1

 

Purchase accounting adjustments

 

0.6

 

 

0.6

 

Adjusted revenue

$

2,223.1

 

$

1,215.7

 

 
Adjusted operating income:
Operating income

$

965.7

 

43.4

%

$

413.7

 

34.0

%

Amortization of intangible assets

 

107.7

 

4.8

%

 

84.0

 

6.9

%

Purchase accounting adjustments

 

9.5

 

0.4

%

 

4.9

 

0.4

%

Asset impairment

 

3.9

 

0.2

%

 

 

0.0

%

Acquisition and divestiture-related costs

 

7.8

 

0.4

%

 

0.3

 

0.0

%

Significant litigation matters and settlements

 

 

0.0

%

 

1.2

 

0.1

%

Restructuring and other, net

 

3.7

 

0.2

%

 

4.3

 

0.4

%

Adjusted operating income

$

1,098.2

 

49.4

%

$

508.5

 

41.8

%

 
(1) amounts may not sum due to rounding

Contacts

Investor Relations:

PerkinElmer, Inc.

Steve Willoughby (781) 663-5677

steve.willoughby@perkinelmer.com

Media Contact:

PerkinElmer, Inc.

Fara Goldberg (781) 663-5699

fara.goldberg@perkinelmer.com

Read full story here

error: Content is protected !!